How Much Does Evenity (Romosozumab) Cost in North Carolina in 2026?

Evenity List Price and Cash-Pay Cost in North Carolina

The wholesale acquisition cost (WAC) for Evenity sits at $1,825 per monthly dose across all U.S. markets, including North Carolina. Each dose consists of two 105 mg/1.17 mL prefilled syringes administered subcutaneously, totaling 210 mg per visit. Over a full 12-month treatment course, the undiscounted sticker price reaches $21,900 before any insurance adjustments or manufacturer rebates.

North Carolina retail pharmacy cash-pay prices in 2026 mirror the national WAC at approximately $1,825 per month. Price variation between pharmacies in cities like Charlotte, Raleigh, and Asheville remains minimal for this specialty biologic because distribution channels are tightly controlled. Evenity is a biologic product regulated under the Public Health Service Act, and no FDA-approved biosimilar exists as of May 2026, which keeps pricing uniform. The FDA's Orange Book lists no generic alternatives.

Patients paying entirely out of pocket should ask their prescribing endocrinologist or rheumatologist about buy-and-bill arrangements, where the provider's office purchases the drug and bills the insurer directly. This model is common for injectable osteoporosis therapies and can reduce the patient's out-of-pocket exposure compared to specialty pharmacy fill-and-ship models. The American Association of Clinical Endocrinology (AACE) 2020 postmenopausal osteoporosis guideline classifies romosozumab as a first-line option for patients at very high fracture risk, which supports medical-necessity arguments for coverage appeals.

Insurance Coverage for Evenity in North Carolina

Most large commercial insurers operating in North Carolina, including Blue Cross Blue Shield of NC, Aetna, Cigna, and UnitedHealthcare, include Evenity on their specialty formularies. Coverage typically requires prior authorization with documentation of at least one of these criteria: a T-score of -2.5 or lower at the lumbar spine or femoral neck, a history of osteoporotic fracture, or failure or intolerance of a first-line antiresorptive such as alendronate or denosumab.

The clinical case for coverage rests on trial data. In the ARCH trial (N=4,093), romosozumab for 12 months followed by alendronate reduced new vertebral fracture risk by 48% compared with alendronate alone at 24 months. The FRAME trial (N=7,180) demonstrated a 73% relative reduction in new vertebral fractures at 12 months versus placebo. These numbers give prior-authorization reviewers a clear efficacy signal. The Endocrine Society's 2019 clinical practice guideline recommends anabolic therapy, including romosozumab, as initial treatment for postmenopausal women with very high fracture risk rather than reserving it for bisphosphonate failures.

Employer-sponsored plans vary. Self-funded ERISA plans may impose step-therapy requirements that demand 12 months of bisphosphonate use before approving Evenity. Patients denied coverage should file a formal appeal citing the ARCH trial's fracture-reduction endpoints and the AACE/Endocrine Society guideline classification.

North Carolina Medicaid and Evenity

North Carolina Medicaid does not cover Evenity for osteoporosis indications. The state's preferred drug list restricts romosozumab coverage to type 2 diabetes-related indications only, an unusual formulary limitation given that romosozumab has no FDA-approved diabetes indication. This creates a practical barrier for the roughly 2.9 million North Carolinians enrolled in Medicaid or NC Health Choice programs.

North Carolina completed its Medicaid managed-care transition in 2024, shifting most beneficiaries into managed-care organizations (MCOs). Each MCO maintains its own formulary, but the state-level exclusion of Evenity for osteoporosis has persisted across all plans. Patients on NC Medicaid who have very high fracture risk may need to pursue an exception request supported by clinical documentation of prior fractures and DXA scores, though approval rates for such exceptions remain low based on provider reports.

Alternative covered agents for NC Medicaid osteoporosis patients include generic alendronate (approximately $4 to $15 per month), zoledronic acid infused annually (the HORIZON trial showed 70% vertebral fracture reduction), and denosumab (Prolia) at roughly $1,100 every six months through the FREEDOM trial data pathway. Teriparatide (Forteo) may also be accessible through Medicaid with prior authorization for patients who have failed bisphosphonates.

The Amgen/UCB Savings Card: How It Works in North Carolina

Amgen and UCB jointly offer a copay savings card for commercially insured patients prescribed Evenity. Eligible patients can reduce their monthly out-of-pocket cost to $0 per dose for up to 12 months. The card covers the difference between the patient's copay or coinsurance obligation and the $0 target, with an annual maximum benefit that typically exceeds $20,000.

Eligibility requirements are straightforward. The patient must carry commercial insurance (not a government program like Medicare, Medicaid, Tricare, or VA benefits), have an active Evenity prescription, and reside in a state where such programs are legal. North Carolina permits manufacturer copay assistance cards without restriction, unlike a small number of states that impose accumulator-adjuster programs.

Patients should confirm whether their insurer uses a copay accumulator or copay maximizer program. These programs, increasingly adopted by pharmacy benefit managers, prevent manufacturer copay card payments from counting toward the patient's annual deductible or out-of-pocket maximum. If a North Carolina patient's plan employs an accumulator, the savings card still reduces monthly payments, but the patient may face a coverage gap later in the plan year. The FDA's approval label for Evenity specifies the 12-dose treatment course, making full-year savings card coverage essential.

503A Compounded Romosozumab in North Carolina

Licensed 503A compounding pharmacies in North Carolina can legally prepare romosozumab formulations under state pharmacy board oversight. North Carolina Board of Pharmacy regulations permit 503A compounding when a prescriber writes a patient-specific prescription and the pharmacy holds a valid NC compounding license. This operates under the Federal Food, Drug, and Cosmetic Act Section 503A, which exempts qualifying compounders from certain FDA manufacturing requirements.

However, compounded romosozumab is not FDA-approved and has not undergone the same bioequivalence testing as the branded Evenity product. There is no standardized pricing benchmark for compounded versions. Availability depends on the specific 503A pharmacy's formulary, sourcing of active pharmaceutical ingredients, and sterility testing protocols. Patients considering this route should discuss it with their prescriber and confirm that the compounding pharmacy performs United States Pharmacopeia (USP) Chapter 797 compliant sterility testing.

The practical reality is that very few 503A pharmacies in North Carolina currently compound romosozumab due to the complexity of biologic manufacturing. Monoclonal antibody production requires cell-culture systems that exceed the capability of most community compounding pharmacies. Patients should verify actual availability before assuming compounding represents a viable cost-reduction pathway.

Telehealth Prescribing of Evenity in North Carolina

North Carolina permits telehealth prescribing of Evenity for follow-up osteoporosis management. The state's telehealth parity law requires commercial insurers to cover telehealth-delivered services at the same rate as in-person visits. An initial evaluation for osteoporosis typically requires an in-person visit for DXA scanning and physical examination, but ongoing monitoring visits during the 12-month romosozumab course can be conducted via video telehealth.

The injection itself is administered in a healthcare setting (clinic, infusion center, or provider office) because Evenity requires subcutaneous injection at two separate sites per dose. Telehealth does not replace the injection visit but can replace interim follow-up appointments where the clinician reviews bone turnover markers such as P1NP (procollagen type I N-terminal propeptide), which peaks within the first month of romosozumab therapy, and CTX (C-terminal telopeptide). The ARCH trial safety monitoring protocol included cardiovascular event surveillance, making periodic check-in visits clinically appropriate.

HealthRX and similar telehealth platforms can coordinate initial evaluations, prior-authorization paperwork, and monthly follow-up visits for North Carolina patients, reducing travel burden for those in rural western NC counties where endocrinology access is limited.

Cardiovascular Safety: What North Carolina Prescribers Screen For

The FDA issued a black-box warning on Evenity's label based on a cardiovascular safety signal identified in the ARCH trial. In that study, major adverse cardiac events (MACE) occurred in 2.5% of romosozumab-treated patients versus 1.9% in the alendronate group over 12 months of treatment. The absolute difference was modest, but the signal was concentrated in the first 12 months.

Romosozumab is contraindicated in patients who have had a myocardial infarction or stroke within the preceding 12 months. North Carolina prescribers should perform a cardiovascular risk assessment before initiating therapy. The 2022 meta-analysis by Lv et al. pooling data from ARCH, FRAME, and BRIDGE found no statistically significant increase in MACE with romosozumab compared with placebo, though the alendronate-controlled comparison in ARCH did reach significance. A systematic review in the Journal of Bone and Mineral Research reached similar conclusions, noting that patient selection can mitigate risk.

Patients with uncontrolled hypertension, prior cardiovascular events, or multiple atherosclerotic risk factors should discuss alternative anabolic agents such as teriparatide or abaloparatide, which do not carry cardiovascular black-box warnings.

Transition Therapy After 12 Months of Romosozumab

Romosozumab's bone-forming effect diminishes after 12 monthly doses as anti-sclerostin antibody exposure triggers compensatory increases in bone resorption markers. The FDA label specifies a maximum treatment duration of 12 months. Discontinuation without antiresorptive follow-on therapy leads to rapid bone mineral density (BMD) loss, a pattern similar to denosumab discontinuation rebound.

The ARCH trial protocol transitioned patients to alendronate 70 mg weekly after completing 12 months of romosozumab, and BMD gains were maintained through 24 months. The FRAME extension transitioned patients to denosumab 60 mg every six months and demonstrated continued BMD accrual at the lumbar spine (total gain of 17.6% at 24 months). For North Carolina patients whose insurance covers denosumab but not a second course of romosozumab, the sequential romosozumab-to-denosumab protocol offers the strongest long-term BMD trajectory.

North Carolina prescribers should schedule the transition therapy prescription before the 12th romosozumab dose to avoid any treatment gap. A lapse of even two to three months can initiate resorption-mediated BMD decline.